Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.05. | Egetis Therapeutics AB: Egetis Confirms Launch of Emcitate in Germany | 298 | GlobeNewswire (Europe) | For investors and media only
Stockholm, Sweden, May 5, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), a pharmaceutical company dedicated to developing therapies... ► Artikel lesen | |
30.04. | Egetis Therapeutics AB: Interim report Q1 2025 | 65 | GlobeNewswire (Europe) | Egetis plans to launch Emcitate® in the first country, Germany, on May 1, 2025The European Commission approved Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency.In... ► Artikel lesen | |
26.02. | Egetis Therapeutics AB: Year-End Report January-December 2024 | 225 | GlobeNewswire (Europe) | European Commission has approved Egetis' Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency· Egetis expects to launch Emcitate in the first country, Germany... ► Artikel lesen | |
20.02. | Egetis Therapeutics to Feature MCT8 Deficiency on Behind the Mystery Airing on Lifetime in Honor of Rare Disease Day | 1 | GlobeNewswire (USA) | ||
EGETIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
13.02. | Egetis Therapeutics AB: European Commission approves Egetis' Emcitate (tiratricol) as the first and only treatment for patients with MCT8 deficiency | 249 | GlobeNewswire (Europe) | Stockholm, Sweden, February 13, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol)... ► Artikel lesen | |
08.11.24 | Egetis Therapeutics AB: Interim report Q3 2024 | 164 | GlobeNewswire (Europe) | Egetis successfully carried out directed share issuances amounting to SEK 300 million· The Company's MAA review for tiratricol (Emcitate®) at the EMA remains on track according to EMA's stipulated... ► Artikel lesen | |
22.08.24 | Egetis Therapeutics AB: Interim report Q2 2024 | 222 | GlobeNewswire (Europe) | New study reports tiratricol (Emcitate®) treatment in patients with MCT8 deficiency is associated with survival benefitsAn Abstract published ahead of the European Thyroid Association's Annual Meeting... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SANOFI | 83,04 | -0,26 % | UBS stuft SANOFI auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Sanofi mit einem Kursziel von 115 Euro auf "Buy" belassen. Matthew Weston ging am Dienstag auf positive Studiendaten eines... ► Artikel lesen | |
GSK | 16,350 | -3,54 % | UBS stuft GSK auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat GSK mit einem Kursziel von 1600 Pence auf "Neutral" belassen. Die Ende Juli anstehenden Quartalszahlen des Pharmakonzerns dürften eine Fortsetzung... ► Artikel lesen | |
ASTRAZENECA | 121,10 | -1,94 % | ANALYSE-FLASH: Berenberg hebt Ziel für Astrazeneca auf 14200 Pence | HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Astrazeneca von 14000 auf 14200 Pence angehoben und die Einstufung auf "Buy" belassen. Analystin Luisa Hector sah in einer am... ► Artikel lesen | |
TILRAY BRANDS | 0,505 | +1,40 % | Söllner: Autowunder BMW, VW! Bitcoin 745.000!? Xiaomi vor Tesla - "Blockbuster" Nvidia, Meta, Tilray | Florian Söllner, leitender Redakteur bei DER AKTIONÄR, blickt jede Woche auf die spannendsten Entwicklungen im Tech-Sektor. Heute geht es um folgende Werte: TripAdvisor, Rocket Lab, Kratos, BWX, Volkswagen... ► Artikel lesen | |
DERMAPHARM | 34,250 | -2,14 % | Dermapharm Holding SE: Klare strategische Ausrichtung und bekräftigter Ausblick für 2025. mwb research bestätigt KAUFEN. | Die Dermapharm Holding SE (DMP) hat auf ihrer Hauptversammlung ihre aktionärsorientierte Strategie und stabile Dividendenpolitik bekräftigt und eine Ausschüttung von EUR 0,90 je Aktie (insgesamt EUR... ► Artikel lesen | |
QUANTUM BIOPHARMA | 15,600 | -1,89 % | Quantum Biopharma Ltd: Quantum Biopharma submits Lucid-21-302 for fast track | ||
TONIX PHARMACEUTICALS | 34,600 | -1,14 % | Tonix up after peer reviewed data for pain therapy and new data for mpox vaccine | ||
CASSAVA SCIENCES | 1,805 | -1,23 % | Cassava Sciences, Inc.: Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development | AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing novel, investigational... ► Artikel lesen | |
OPKO HEALTH | 1,105 | +0,04 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,588 | +1,15 % | Krebsforschungs-Expertin verstärkt wissenschaftlichen Beirat von SELLAS Life Sciences | ||
SOLIGENIX | 1,270 | 0,00 % | SOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results | PRINCETON, N.J., May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
BETTERLIFE PHARMA | 0,051 | 0,00 % | BetterLife Pharma Inc.: BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders | VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on... ► Artikel lesen | |
THERIVA BIOLOGICS | 0,507 | +8,22 % | Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Canc | - Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology... ► Artikel lesen | |
VALEO PHARMA | 0,005 | 0,00 % | Valeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc. | ||
NOVABAY PHARMACEUTICALS | 0,690 | +7,83 % | NovaBay Pharmaceuticals, Inc. - 10-Q, Quarterly Report |